KRRO Korro Bio
- 65.730
- +5.600+9.31%
Korro Bio News
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $115
Korro Bio's Promising Regulatory and Preclinical Advances Earn a Buy Rating From Analyst Mitchell Kapoor
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Collegium Pharmaceutical (COLL) and Korro Bio (KRRO)
RBC Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Raises Target Price to $105
Raymond James Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $153
RBC Raises Price Target on Korro Bio to $105 From $95, Keeps Outperform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
Korro Bio Initiated With a Strong Buy at Raymond James
Korro Bio Is Maintained at Buy by HC Wainwright & Co.
Korro Bio Analyst Ratings
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Raises Target Price to $115
Promising RNA Editing Developments and KRRO-110 Potential Drive Buy Rating for Korro Bio
BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
RBC Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $95
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180
BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
Korro Bio Analyst Ratings
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $100
Analysis
Price Target
No Data
No Data